Follow-up on the safety of ALLO-ASC-CD for Crohn's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational follow-up study evaluates the safety of ALLO-ASC-CD, an intravenous infusion of allogenic adipose-derived mesenchymal stem cells, in patients previously treated in the ALLO-ASC-CD-101 clinical trial. The study will monitor participants for 36 months to assess any safety concerns related to the treatment. The approach focuses on the potential of these stem cells to reduce inflammation and modulate the immune response in individuals with Crohn's disease. By tracking the long-term effects, the study aims to provide valuable insights into the safety profile of this innovative treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subjects who are injected with ALLO-ASC-CD in phase 1 clinical trial of ALLO-ASC-CD-101.
2. Subjects who are able to give written informed consent prior to study start and to comply with the study requirements.

Exclusion Criteria:

1\. Subjects who are considered not suitable for the study by the principal investigator.

Where it's running

• Seoul National University Hospital
  Seoul, South Korea Recruiting
• Severance Hospital
  Seoul, South Korea Completed

Study contacts

• Principal investigator: Jae Hee Cheon, Ph D — Yonsei University
• Study coordinator: Jae Hee Cheon, Ph D
• Email: GENIUSHEE@yuhs.ac

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Microencapsulated Propionate vs Butyrate for Crohn's Disease in Remission

  This study tests whether microencapsulated sodium propionate can favorably alter the gut microbiota and inflammation in adults with Crohn’s disease, compared with sodium butyrate.

  Recruiting University of Padova · Padova · NCT07883044

• Risankizumab for Refractory Perianal Fistulizing Crohn's Disease

  This study tests whether risankizumab can help people with Crohn’s disease who have draining perianal fistulas not responding to other treatments.

  Recruiting Phase 4 Hyogo Medical University · Nishinomiya and 3 other locations · NCT07872449

• Intestinal ultrasound-guided management for inflammatory bowel disease

  This study tests if adding point-of-care intestinal ultrasound at every visit changes treatment decisions for adults with Crohn’s disease or ulcerative colitis undergoing disease assessment.

  Recruiting Mahidol University · Bangkok · NCT07775352

• Laser-based sizing of GI lesions during endoscopies

  This study tests whether the AccuMeasure laser tool gives more accurate and reliable lesion size measurements during colonoscopies for adults with colon polyps or Crohn’s disease than traditional endoscopic estimates.

  Recruiting Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Quebec · NCT07770425

• A Probiotic Approach to Modulating Gut Microbiota in Mild-to-Moderate Ulcerative Colitis

  A specific probiotic given rectally will be tested in adults with mild-to-moderate ulcerative colitis to see if it can help manage symptoms.

  Recruiting Catholic University of the Sacred Heart · Roma, RM · NCT07724990

• Claudin-2 Immunostaining to Detect Active or Inactive Inflammation in IBD Biopsies

  This study tests whether staining for Claudin-2 in intestinal biopsy samples can help identify active vs. inactive inflammation in people with ulcerative colitis or Crohn's disease.

  Recruiting IRCCS Policlinico S. Donato · San Donato Milanese, Mi · NCT07710287

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.